|
Basal cell
carcinoma
Basal cell
carcinoma
(BCC) is the
most common
form of skin
cancer. It
can be
destructive
and
disfiguring.
The risk of
developing
BCC is
increased
for
individuals
with a
family
history of
the disease
and a high
cumulative
exposure to
UV light via
sunlight or,
in the past,
carcinogenic
chemicals
especially
arsenic.
Treatment is
with
surgery,
topical
chemotherapy,
x-ray,
cryosurgery,
photodynamic
therapy. It
is rarely
life-threatening
but if left
untreated
can be
disfiguring,
cause
bleeding and
produce
local
destruction
(eg., eye,
ear, nose,
lip).
Forms
Various
forms are
recognised:
*
Nodular:
flesh-colored
papule with
telangiectasis.
If it
ulcerates,
it becomes a
"rodent
ulcer" (ulcus
rodens), an
ulcerating
nodule with
(often) a
pearly
border.
*
Cystic:
rarer and
hard to
distinguish
from the
nodular
form. It has
a central
cavity with
fluid.
*
Pigmented: a
variant of
the nodular
form that
may be
confused
with
melanoma.
*
Sclerosing/cicratising:
a scar-like
lesion.
*
Superficial:
a red
scaling
patch
About
two-thirds
of basal
cell
carcinomas
occur on
sun-exposed
areas of the
body.
One-third
occur on
areas of the
body that
are not
exposed to
sunlight,
emphasizing
the genetic
susceptibility
of the basal
cell cancer
patients.
Presentation
Presents as
a firm
nodule,
clearly
growing
within the
skin and
below it,
rather than
on the
surface.
Color varies
from that of
normal skin
to dark
brown or
black, but
there is a
characteristic
"pearly
white"
translucent
quality on
the
periphery.
Characteristic
"rolled
edge". Once
the basal
cells have
invaded the
deeper
tissues the
rolled edge
disappears.
When BCCs
occur at
sites other
than the
face and
neck they
are usually
just red,
flat,
scaling
areas. Thus
superficial
BCCs can
often be
confused
with a patch
of eczema.
Diagnosis
To diagnose,
a biopsy
(where
tissue is
taken for
pathological
study) is
done using
local
anesthesia.
In small
lesions, the
tumor is
generally
removed in
its
entiriety,
while larger
ones are
biopsied
first and
surgically
removed
later if it
is confirmed
that it is
malignant.
Histopathology:
Basal cell
carcinoma is
a malignant
epithelial
tumor
arising only
in skin,
from the
basal layer
of the
epidermis or
of the
pilosebaceous
adnexa.
Tumor is
represented
by compact
areas, well
delineated
and invading
the dermis,
apparent
with no
connection
with the
epidermis.
Tumor cells
resemble
normal basal
cells
(small,
monomorphous)
are disposed
in palisade
at the
periphery of
the tumor
nests, but
are
spindle-shaped
and
irregular in
the middle.
Tumor
clusters are
separated by
a reduced
stroma with
inflammatory
infiltrate.
Pathophysiology
Basal cell
carcinomas
develop in
the basal
cell layer
of the skin.
Sunlight
exposure
leads to the
formation of
thymine
dimers, a
form of DNA
damage.
While DNA
repair
removes most
UV-induced
damage, not
all
crosslinks
are excised.
There is,
therefore,
cumulative
DNA damage
leading to
mutations.
Apart from
the
mutagenesis,
sunlight
depresses
the local
immune
system,
possibly
decreasing
immune
surveillance
for new
tumor cells.
Prevention
and Early
Diagnosis
Basal cell
carcinoma is
the most
common skin
cancer. It
occurs
mainly in
fair-skinned
patients
with a
family
history of
this cancer.
Sunlight is
a factor in
about two
thirds of
these
cancers, but
one third
occur in non
sun-exposed
areas.
Therefore,
dermatologists
recommend
sun screens
and annual
skin cancer
exams to
prevent or
provide
early
detection of
this common
tumor.
Treatment
Most basal
cell
carcinomas
are removed
surgically.
A common
method is
"electrodessication
and
curettage"
(ED&C). This
is done by
scraping the
tumor out
with a
curette and
cauterizing
the base and
margins. The
wound is
left to heal
by itself
(secondary
intention
healing).
The cure
rate and
cosmetic
result are
excellent,
especially
in concave
areas. It is
also the
most cost
effective
treatment.
Surgical
excision by
the
dermasurgeon
is another
option with
the margins
of excised
tissue
examined
under the
microscope.
Certain
types, like
the
sclerosing
basal cell
cancers may
need a wider
margin, as
they develop
subtle
processes
that project
outside the
visible part
of the
tumor.
Although
BCCs are
termed
carcinomas,
they are not
invasive
cancers -
and are
therefore
not included
in national
cancer
statistics.
Some
superficial
cancers
respond to
local
therapy with
5-fluorouracil,
a
chemotherapy
agent.
Topical
treatment
with 5%
IMIQUIMOD
cream (see
below also),
with 5
applications
per week for
six weeks
has a
reported 70
- 90%
success rate
at reducing,
even
removing the
BCC [basal
cell
carcinoma].
Imiquimod
may be used
prior to
surgery to
reduce the
size of the
carcinoma.
See
Chemotherapy.
One can
expect a
great deal
of
inflammation
with this
treatment.
Mohs
micrographic
surgery has
the highest
cure rate
and is
especially
indicated
for
recurrent
tumors or
tumors in
areas (eg.
eyelid or
nose) where
minimal
amounts of
tissue
removal are
important.
Mohs surgery
involves
checking the
base and
edges under
a microscope
before the
surgical
repair of
the site.
Specially
trained
dermasurgeons
do this
procedure,
usually
in-office.
A new immune
enhancement
agent
(topical
imiquimod, "Aldara")
is effective
for the
treatment of
superficial
skin cancers
(basal cell
and squamous
cell cancer,
and even
malignant
melanoma
in-situ). It
is also used
pre-operatively
to shrink
nodular
basal cell
cancers,
thus
allowing a
smaller
surgical
excision.
X-ray is
still
appropriate
in older
patients who
are not
candidates
for surgery.
Cryosurgery
is another
option,
particularly
for basal
cell cancer
invading
cartilage,
as the
healthy
cartilage is
cryo-resistant.
Treating
surgeons (dermasurgeons,
plastic
surgeons, or
other
specialists)
will
recommend
one of these
modalities
as
appropriate
treatment
depending on
the tumor
size,
location,
patient age
and other
variables.
There is
also a new
treatment
using
Euphorbia
peplus a
common
garden weed.
Prognosis
Although
basal cell
carcinoma
rarely
metastasizes,
it grows
locally
without
stopping.
The cancer
can impinge
on vital
structures
and result
in loss
extension or
loss of
function or
rarely
| |